Eloxx Pharmaceuticals, Inc. (ELOX)
12.75
-0.40
(-3.04%)
USD |
OTCM |
Nov 16, 16:00
Eloxx Pharmaceuticals Enterprise Value : -4.166M for Nov. 16, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 16, 2026 | -4.166M |
| November 13, 2026 | -2.531M |
| November 12, 2026 | -3.594M |
| November 11, 2026 | -3.103M |
| November 10, 2026 | -3.553M |
| November 09, 2026 | -1.06M |
| November 06, 2026 | -5.433M |
| November 05, 2026 | -3.962M |
| November 04, 2026 | -4.207M |
| November 03, 2026 | -3.471M |
| November 02, 2026 | -3.798M |
| October 30, 2026 | -1.305M |
| October 29, 2026 | -2.327M |
| October 28, 2026 | -2.654M |
| October 27, 2026 | -1.755M |
| October 26, 2026 | -2.450M |
| October 23, 2026 | -3.962M |
| October 22, 2026 | -2.654M |
| October 21, 2026 | -1.918M |
| October 20, 2026 | -2.245M |
| October 19, 2026 | -5.188M |
| October 16, 2026 | -3.022M |
| October 15, 2026 | -0.2836M |
| October 14, 2026 | -6.373M |
| October 13, 2026 | -4.370M |
| Date | Value |
|---|---|
| October 12, 2026 | 0.4929M |
| October 09, 2026 | -0.1201M |
| October 08, 2026 | 5.765M |
| October 07, 2026 | 4.539M |
| October 06, 2026 | 5.560M |
| October 05, 2026 | 6.704M |
| October 02, 2026 | 7.113M |
| October 01, 2026 | 7.930M |
| September 30, 2026 | 6.296M |
| September 29, 2026 | 0.2753M |
| September 28, 2026 | -1.42M |
| September 25, 2026 | -1.299M |
| September 24, 2026 | 2.616M |
| September 23, 2026 | 0.3358M |
| September 22, 2026 | 5.563M |
| September 21, 2026 | 7.420M |
| September 18, 2026 | 8.469M |
| September 17, 2026 | 8.873M |
| September 16, 2026 | 9.196M |
| September 15, 2026 | 11.70M |
| September 14, 2026 | 3.827M |
| September 11, 2026 | 1.607M |
| September 10, 2026 | 3.747M |
| September 09, 2026 | 4.917M |
| September 08, 2026 | 3.303M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Filana Therapeutics, Inc. | -54.71M |
| CorMedix, Inc. | 172.70M |
| Breakthrough Chemistry, Inc. | 0.0854M |
| BioStem Technologies, Inc. | 18.11M |
| Cardiac Biotech Solutions, Inc. | 6.406M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.543M |
| Total Expenses (Quarterly) | 5.543M |
| EPS Diluted (Quarterly) | -0.486 |
| Earnings Yield | -20.29% |
| Normalized Earnings Yield | -21.69 |